Holen Sie sich die Stockscreener-App
2.87
1.20%
-0.04
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ESPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$2.91
Offen:
$2.95
24-Stunden-Volumen:
4.66M
Relative Volume:
0.98
Marktkapitalisierung:
$686.11M
Einnahmen:
$116.33M
Nettoeinkommen (Verlust:
$-209.25M
KGV:
-1.3538
EPS:
-2.12
Netto-Cashflow:
$-135.49M
1W Leistung:
-13.66%
1M Leistung:
-15.94%
6M Leistung:
+13.64%
1J Leistung:
+62.43%
1-Tages-Spanne:
$2.75
$3.02
1-Wochen-Bereich:
$2.75
$3.385
52-Wochen-Spanne:
$0.6925
$4.175
Esperion Therapeutics Inc Stock (ESPR) Company Profile
Firmenname
Esperion Therapeutics Inc
Sektor
Telefon
734-887-3903
Adresse
3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI
Compare ESPR vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESPR
Esperion Therapeutics Inc
|
2.87 | 695.67M | 116.33M | -209.25M | -135.49M | -2.12 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.21 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.81 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.46 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.44 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
487.53 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Eingeleitet | Piper Sandler | Overweight |
| 2024-12-18 | Eingeleitet | Goldman | Neutral |
| 2024-12-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-06-20 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2024-01-03 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-01 | Hochstufung | Northland Capital | Under Perform → Market Perform |
| 2023-06-15 | Hochstufung | BofA Securities | Underperform → Buy |
| 2023-03-16 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-03-16 | Herabstufung | Northland Capital | Market Perform → Under Perform |
| 2023-03-07 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2023-02-27 | Fortgesetzt | BofA Securities | Neutral |
| 2023-02-24 | Hochstufung | Jefferies | Hold → Buy |
| 2023-02-03 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-08-03 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2022-05-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-19 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2021-10-14 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-05-05 | Herabstufung | Stifel | Buy → Hold |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2021-03-11 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-02-12 | Herabstufung | Jefferies | Buy → Hold |
| 2021-02-09 | Herabstufung | Goldman | Neutral → Sell |
| 2021-01-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-11-10 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2020-09-29 | Fortgesetzt | JP Morgan | Underweight |
| 2020-08-11 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2020-04-01 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-03-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-24 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2020-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-16 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-29 | Herabstufung | Goldman | Neutral → Sell |
| 2019-05-06 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-04-26 | Hochstufung | Goldman | Sell → Neutral |
| 2019-03-13 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2019-01-07 | Bestätigt | Needham | Strong Buy |
| 2018-12-13 | Eingeleitet | Goldman | Sell |
| 2018-10-29 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2018-10-16 | Eingeleitet | BTIG Research | Buy |
| 2018-08-17 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-07-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2018-05-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2018-05-02 | Herabstufung | BofA/Merrill | Buy → Underperform |
Alle ansehen
Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten
electroCore, Inc. (ECOR) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz
ESPR to Boost Cardiovascular Portfolio With Corstasis Buyout for $75M - TradingView
Esperion Therapeutics Inc (ESPR) Strengthens Business Outlook Amid Strategic Agreements - Yahoo Finance UK
Esperion to acquire Corstasis for cardiovascular franchise expansion - Pharmaceutical Technology
Esperion Therapeutics: $75 Million Acquisition Of Corstasis To Expand Cardiovascular Franchise With Enbumyst Nasal Spray - Pulse 2.0
Deal Watch: Esperion Augments Cardiovascular Franchise Via Corstasis Buyout - Citeline News & Insights
Esperion Therapeutics (NASDAQ:ESPR) Shares Down 13.1%Should You Sell? - MarketBeat
Ann Arbor pharmaceutical company to pay $75M in deal for new drug - Crain's Detroit Business
Esperion Therapeutics (NASDAQ:ESPR) Given New $5.00 Price Target at Needham & Company LLC - MarketBeat
Esperion to acquire Corstasis Therapeutics - The Pharma Letter
Esperion Acquires Enbumyst Maker Corstasis - Bitget
Esperion Acquires Enbumyst Maker Corstasis - Benzinga
Esperion to Acquire Corstasis, Expanding Heart Failure Portfolio - TipRanks
Esperion Therapeutics to Acquire Corstasis for $75 Million Upfront, Plus Up to $180 Million Milestones - TradingView
Esperion (NASDAQ: ESPR) adds Enbumyst CHF drug in Corstasis acquisition - Stock Titan
Esperion Therapeutics to Acquire Corstasis for $75 Million in Cash - marketscreener.com
Esperion Therapeutics to acquire Corstasis Therapeutics, expands cardiovascular portfolio with Enbumyst nasal spray - Traders Union
Esperion to acquire Enbumyst maker for $75M plus milestones - Investing.com
ESPR: Acquisition brings a novel FDA-approved nasal spray diuretic, expanding cardiovascular offerings - TradingView
Esperion Therapeutics and Corstasis Therapeutics Announce - GlobeNewswire
ESPR Should I Buy - Intellectia AI
ESPR SEC FilingsEsperion Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Esperion Therapeutics Inc devrait afficher une perte de 13 cents par actionEarnings AVANT-PAPIER - TradingView
Esperion Therapeutics (ESPR) Earnings Expected to Grow: Should You Buy? - Finviz
Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10 - The Manila Times
Cholesterol drug biopharma Esperion sets March 10 results webcast - Stock Titan
Esperion Therapeutics (ESPR) to Release Earnings on Tuesday - MarketBeat
How Esperion Therapeutics Inc. stock benefits from tech adoption2025 Biggest Moves & Technical Entry and Exit Tips - mfd.ru
Why is Esperion Therapeutics Inc. stock going upJuly 2025 EndofMonth & Free Community Consensus Stock Picks - mfd.ru
Aug Setups: Can Esperion Therapeutics Inc outperform under higher oil pricesQuarterly Risk Review & Capital Efficient Trading Techniques - baoquankhu1.vn
Esperion to Participate in The 2026 Citizens Life Sciences Conference - Bitget
Esperion settles another lawsuit to keep generic versions of popular drug off shelves - Cardiovascular Business
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL and NEXLIZET Prior to April 19, 2040 - marketscreener.com
How to listen to Esperion at the 2026 Citizens Life Sciences event - Stock Titan
Setup Watch: What is the next catalyst for Esperion Therapeutics IncWeekly Risk Report & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Esperion Therapeutics: Past The Turnaround, Waiting On Guidelines (NASDAQ:ESPR) - Seeking Alpha
Esperion Therapeutics (ESPR) has signed a settlement agreement with a fifth generic drug applicant. - Bitget
Esperion settles patent dispute with Alkem over cholesterol drugs - Investing.com
Esperion and Alkem Laboratories Settle Patent Litigation Over NEXLETOL and NEXLIZET - Quiver Quantitative
Esperion Reaches Settlement Agreement with Fifth ANDA Filer Not to Market Generic Version of NEXLETOL (bempedoic acid) & NEXLIZET (bempedoic acid & ezetimibe) Prior to April 19, 2040 - Bitget
Esperion Reaches Settlement Agreement with Fifth ANDA Filer - GlobeNewswire
Aug Volume: Is Esperion Therapeutics Inc. still a buy after recent gains2025 Key Highlights & Free Community Consensus Stock Picks - mfd.ru
Gibson Energy Inc. (OTCMKTS:GBNXF) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
What’s the fair value of Esperion Therapeutics Inc. stockAnalyst Upgrade & Low Risk High Reward Ideas - mfd.ru
Esperion Therapeutics (NASDAQ:ESPR) Downgraded by Wall Street Zen to "Hold" - MarketBeat
What is the next catalyst for Esperion Therapeutics Inc.Stock Surge & Weekly Return Optimization Plans - mfd.ru
Is Esperion Therapeutics Inc. in a bullish channelJuly 2025 Price Swings & Weekly Chart Analysis and Trade Guides - mfd.ru
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Sahm
Market Trends: How does Esperion Therapeutics Inc. score in quality rankings2025 Key Highlights & Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
What is the next catalyst for Esperion Therapeutics IncWeekly Investment Report & Expert Curated Trade Setups - baoquankhu1.vn
Finanzdaten der Esperion Therapeutics Inc-Aktie (ESPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
0.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):